BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Show more

Location: Bellevue Centre, West Vancouver, BC, V7T 2X1, Canada | Website: https://briacell.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

19.83M

52 Wk Range

$0.35 - $9.82

Previous Close

$2.91

Open

$2.29

Volume

6,646,073

Day Range

$2.05 - $2.36

Enterprise Value

6.987M

Cash

12.46M

Avg Qtr Burn

-6.018M

Insider Ownership

7.33%

Institutional Own.

10.88%

Qtr Updated

04/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.